2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2618

Lupus Disease Activity Severely Impairs Pandemic Influenza A/H1N1 Vaccine Immune Response in Patients without Therapy
Abstract Number: 1440

Lupus-Prone Mice Demonstrate Enhanced Neutrophil Extracellular Trap Formation: Implications for Autoantibody Formation and Organ Damage
Abstract Number: 2570

Lymphoma Risk in Systemic Lupus: Effects of Disease Activity Versus Treatment
Abstract Number: 2522

M-Ficolin, an Activator of the Complement System, Is the Strongest Predictor of Both DAS28 Remission and Low Disease Activity in a Cohort of 180 Early DMARD Naïve Rheumatoid Arthritis Patients Followed in the Opera-Study
Abstract Number: 1798

Macrophage Migration Inhibitory Factor Regulates Dual-Specificity Phosphatases Via Glucocorticoid Induced Leucine Zipper
Abstract Number: 1800

Macrophages in Hypoxic Rheumatoid Joints Preferentially Express Hypoxia Inducible Transcription Factor-2
Abstract Number: 1037

Magnetic Resonance Imaging (MRI) Assessment of Inflammatory Myopathy: Quantitative Fat-Corrected Muscle T2 and Conventional T2 Measurement Versus Standard MRI and Clinical Metrics
Abstract Number: 1021

Magnetic Resonance Imaging in Follow-up of Clinical Remission in Juvenile Idiopathic Arthritis
Abstract Number: 1051

Magnetic Resonance Imaging in Inflammatory Bowel Disease Patients with Arthralgia
Abstract Number: 2034

Magnetic Resonance Imaging Is a Reliable Tool to Monitor Chronic Non-Bacterial Osteomyelitis in Children
Abstract Number: 2488

Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
Abstract Number: 2585

Magnetic Resonance Imaging Versus Dual Energy Computed Tomography for Detection of Joint Pathology in Gout
Abstract Number: 2142

Magnetic Resonance Imaging-Proven Osteitis At Baseline Predicts the Early Rheumatoid Arthritis Patients Who Will Develop Rapid Radiographic Progression: MRI Is Beneficial to Find the Window of Opportunity in Early RA
Abstract Number: 2221

Major Adverse Cardiovascular Events Are More Common in Rheumatoid Arthritis Than in Psoriatic Arthritis and Are Associated with Different Risk Factors
Abstract Number: 1437

Majority of Lupusqol Domains Are Negatively Correlated with Systemic Lupus Activity Questionnaire (SLAQ) Score

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].